<DOC>
	<DOCNO>NCT03050437</DOCNO>
	<brief_summary>It establish whether platinum-based doublet well single agent chemotherapy EGFR mutant NSCLC patient fail first-line EGFR TKI . In prospective trial , investigator try evaluate whether progression-free survival pemetrexed/cisplatin ( PC ) regimen longer pemetrexed single ( P ) regimen NSCLC patient progress first line treatment EGFR-TKI .</brief_summary>
	<brief_title>A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone NSCLC Patients Who Have Progressed First Line EGFR-TKI</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Histologically confirm nonsquamous NSCLC activate EGFR mutation ( exon 19 deletion exon 21 L858R mutation ) Stage IIIb , IV recurrent NSCLC ( AJCC 7th criterion ) Age ≥ 20 year ECOG performance status 0 1 At least one measurable lesion RECIST 1.1 Progression first line treatment EGFR TKIs advance NSCLC Asymptomatic brain metastasis symptomatic brain metastasis treat local treatment operation , whole brain radiotherapy , gammaknife surgery At least 2 week later whole brain radiotherapy palliative radiotherapy Adequate renal function : estimate creatinine clearance ≥ 45 mL/min Organ function evidence follow ; Absolute neutrophil count &gt; 1.5 x 109/L ; platelet &gt; 100 x 109/L ; total bilirubin ≤1.5 UNL ; AST and/or ALT &lt; 3 UNL , case know hepatic metastasis , AST/ALT &lt; 5 UNL Written inform consent form No previous systemic chemotherapy Uncontrolled systemic illness DM , CHF , unstable angina , hypertension arrhythmia Patients postobstructive pneumonia uncontrolled serious infection Pregnant nursing woman ( Women reproductive potential agree use effective contraceptive method ) Uncontrolled symptomatic brain metastasis Presence third space fluid control drainage Prior history malignancy within 5 year study entry except adequately treat basal cell squamous cell skin cancer situ cervical cancer , welltreated thyroid cancer .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Failed First Line EGFR-TKI</keyword>
	<keyword>EGFR Activating Mutation</keyword>
	<keyword>Pemetrexed</keyword>
</DOC>